Picomolar inhibitors of HIV-1 reverse transcriptase: Design and crystallography of naphthyl phenyl ethers

ACS Medicinal Chemistry Letters

Volumn 5, Issue 11, 2014, Pages 1259-1262

  Lee, Won Gil ^a   Frey, Kathleen M ^b   Gallardo Macias, Ricardo ^a   Spasov, Krasimir A ^b   Bollini, Mariela ^a   Anderson, Karen S ^b   Jorgensen, William L ^a  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anti HIV agents; NNRTIs; protein crystallography

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIPHENYL ETHER DERIVATIVE; EFAVIRENZ; ETRAVIRINE; NAPHTHALENE DERIVATIVE; NAPHTHYL PHENYL ETHER DERIVATIVE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PIROXICAM; RILPIVIRINE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; EC50; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HYDROGEN BOND; MOLECULAR WEIGHT; MONTE CARLO METHOD; MUTATION; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; T LYMPHOCYTE; WILD TYPE;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84925946409     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml5003713     Document Type: Article

References (18)

1. De Clercq, E. The Nucleoside Reverse Transcriptase Inhibitors, Nonnucleoside Reverse Transcriptase Inhibitors, and Protease Inhibitors in the Treatment of HIV Infections (AIDS) Adv. Pharmacol. 2013, 67, 317-358
2. Reynolds, C.; de Koning, C. B.; Pelly, S. C.; van Otterlo, W. A. L.; Bode, M. L. In Search of a Treatment for HIV: Current Therapies and the Role of Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs) Chem. Soc. Rev. 2012, 41, 4657-4670
3. Zhan, P.; Chen, X.; Li, D.; Fang, Z.; De Clercq, E.; Liu, X. HIV-1 NNRTIs: Structural Diversity, Pharmacophore Similarity, and Implications for Drug Design Med. Res. Rev. 2013, 33, E1-E72
4. Bollini, M.; Domaoal, R. A.; Thakur, V. V.; Gallardo-Macias, R.; Spasov, K. A.; Anderson, K. S.; Jorgensen, W. L. Computationally-Guided Optimization of a Docking Hit to Yield Catechol Diethers as Potent Ani-HIV Agents J. Med. Chem. 2011, 54, 8582-8591
5. Lee, W.-G.; Gallardo-Macias, R.; Frey, K. M.; Spasov, K. A.; Bollini, M.; Anderson, K. S.; Jorgensen, W. L. Picomolar Inhibitors of HIV Reverse Transcriptase Featuring Bicyclic Replacement of a Cyanovinylphenyl Group J. Am. Chem. Soc. 2013, 135, 16705-16713
6. de Béthune, M.-P. Non-nucleoside Reverse Transcriptase Inhibitors (NNRTIs), Their Discovery, Development, and Use in the Treatment of HIV-1 Infection: A Review of the Last 20 Years (1989-2009) Antiviral Res. 2010, 85, 75-90
7. Frey, K. M.; Bollini, M.; Mislak, A. C.; Cisneros, J. A.; Gallardo-Macias, R.; Jorgensen, W. L.; Anderson, K. S. Crystal Structures of HIV-1 Reverse Transcriptase with Picomolar Inhibitors Reveal Key Interactions for Drug Design J. Am. Chem. Soc. 2012, 134, 19501-19503
8. Frey, K. M.; Gray, W. T.; Spasov, K. A.; Bollini, M.; Gallardo-Macias, R.; Jorgensen, W. L.; Anderson, K. S. Structure-Based Evaluation of C5 Derivatives in the Catechol Diether Series Targeting HIV-I Reverse Transcriptase Chem. Biol. Drug Des. 2014, 83, 541-549
9. Baka, E.; Comer, J. E. A; Takács-Novák, K. Study of Equilibrium Solubility Measurement by Saturation Shake-Flask Method Using Hydrochlorothiaide as Model Compound J. Pharm. Biomed. Anal. 2008, 46, 335-341
10. Lin, T. S.; Luo, M. Z.; Liu, M. C.; Pai, S. B.; Dutschman, G. E.; Cheng, Y. C. Antiviral Activity of 2′,3′-Dideoxy-β- l -5-fluorocytidine (β- l -EddC) and 2′,3′-Dideoxy-β- l -cytidine (β- l -ddC) against Hepatitis B Virus and Human Immunodeficiency Virus Type 1 in Vitro Biochem. Pharmacol. 1994, 47, 171-174
11. Ray, A. S.; Yang, Z.; Chu, C. K.; Anderson, K. S. Novel Use of a Guanosine Prodrug Approach to Convert 2′,3′-Didehydro-2′,3′-dideoxyguanosine into a Viable Antiviral Agent Antimicrob. Agents Chemother. 2002, 46, 887-891
12. Morelock, M. M.; Choi, L. L.; Bell, G. L.; Wright, J. L. Estimation and Correlation of Drug Water Solubility with Pharmacological Parameters Required for Biological Activity J. Pharm. Sci. 1994, 83, 948-952
13. Weuts, I.; Van Dycke, F.; Voorspoels, J.; de Cort, S.; Stokbroekx, S.; Leemans, R.; Brewster, M. E.; Xu, D.; Segmuller, B.; Turner, Y. T. A.; Roberts, C. J.; Davies, M. C.; Qi, S.; Craig, D. Q. M.; Reading, M. Physicochemical Properties of the Amorphous Drug, Cast Films, and Spray Dried Powders to Predict Formulation Probability of Success for Solid Dispersions: Etravirine J. Pharm. Sci. 2011, 100, 260-274
14. Janssen, P. A. J.; Lewi, P. J.; Arnold, E.; Daeyaert, F.; de Jonge, M.; Heeres, J.; Koymans, L.; Vinkers, M.; Guillemont, J.; Pasquier, E.; Kukla, M.; Ludovici, D.; Andries, K.; de Béthune, M.-P.; Pauwels, R.; Das, K.; Clark, A. D., Jr.; Frenkel, Y. V.; Hughes, S. H.; Medaer, B.; De Knaep, F.; Bohets, H.; De Clerck, F.; Lampo, A.; Williams, P.; Stoffels, P. In Search of a Novel Anti-HIV Drug: Multidisciplinary Coordination in the Discovery of 4-[[4-[[4-[(1 E)-2-Cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, Rilpivirine) J. Med. Chem. 2005, 48, 1901-1919
15. Sun, L.-Q.; Qin, B.; Huang, L.; Qian, K.; Chen, C.-H.; Lee, K.-H.; Xie, L. Optimization of 2,4-Diarylanilines As Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors Bioorg. Med. Chem. Lett. 2012, 22, 2376-2379
16. Jorgensen, W. L.; Duffy, E. M. Prediction of Drug Solubility from Structure Adv. Drug Delivery Rev. 2002, 54, 355-366
17. Bollini, M.; Cisneros, J. A.; Spasov, K. A.; Anderson, K. S.; Jorgensen, W. L. Optimization of Diarylazines As Anti-HIV Agents with Dramatically Enhanced Solubility Bioorg. Med. Chem. Lett. 2013, 23, 5213-5216
18. Jorgensen, W. L. Efficient Drug Lead Discovery and Optimization Acc. Chem. Res. 2009, 42, 724-733